A detailed history of Aton Ra Partners transactions in Dexcom Inc stock. As of the latest transaction made, Aton Ra Partners holds 8,296 shares of DXCM stock, worth $617,720. This represents 2.05% of its overall portfolio holdings.

Number of Shares
8,296
Previous 8,943 7.23%
Holding current value
$617,720
Previous $834,000 23.38%
% of portfolio
2.05%
Previous 1.75%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 05, 2024

SELL
$75.49 - $124.16 $48,842 - $80,331
-647 Reduced 7.23%
8,296 $1.03 Million
Q3 2023

Oct 25, 2023

SELL
$86.06 - $137.93 $18,244 - $29,241
-212 Reduced 2.32%
8,943 $834,000
Q2 2023

Jul 18, 2023

SELL
$112.47 - $130.98 $380,935 - $443,629
-3,387 Reduced 27.01%
9,155 $1.18 Million
Q1 2023

May 05, 2023

SELL
$104.0 - $122.92 $183,456 - $216,830
-1,764 Reduced 12.33%
12,542 $1.46 Million
Q4 2022

Feb 02, 2023

SELL
$84.98 - $122.67 $94,752 - $136,777
-1,115 Reduced 7.23%
14,306 $1.62 Million
Q3 2022

Nov 14, 2022

BUY
$76.35 - $94.18 $68,485 - $84,479
897 Added 6.18%
15,421 $1.24 Million
Q2 2022

Aug 15, 2022

BUY
$67.99 - $132.89 $632,374 - $1.24 Million
9,301 Added 178.08%
14,524 $1.08 Million
Q1 2022

May 16, 2022

SELL
$94.08 - $130.2 $192,487 - $266,389
-2,046 Reduced 28.15%
5,223 $2.67 Million
Q4 2021

Feb 14, 2022

SELL
$129.87 - $162.82 $121,428 - $152,236
-935 Reduced 11.4%
7,269 $3.9 Million
Q3 2021

Nov 15, 2021

BUY
$106.71 - $143.18 $83,020 - $111,394
778 Added 10.48%
8,204 $4.49 Million
Q2 2021

Aug 12, 2021

BUY
$80.99 - $107.93 $221,750 - $295,512
2,738 Added 58.4%
7,426 $3.17 Million
Q1 2021

May 17, 2021

BUY
$84.79 - $104.74 $168,816 - $208,537
1,991 Added 73.82%
4,688 $1.69 Million
Q4 2020

Feb 19, 2021

BUY
$78.0 - $104.5 $210,366 - $281,836
2,697 New
2,697 $997,000

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $28.8B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track This Portfolio

Track Aton Ra Partners Portfolio

Follow Aton Ra Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aton Ra Partners, based on Form 13F filings with the SEC.

News

Stay updated on Aton Ra Partners with notifications on news.